The FDA has granted Ampio Pharmaceuticals approval for its oral drug Optina to address diabetic macular edema. The drug obtained 505-b-2 status last year, making it eligible for approval based on a single study.
Published in Brief:
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||